Citigroup stock

Citigroup Faces Growing Troubles: Could the Industry Be at Risk?

Citigroup stock

The most critical earnings set for investors to look over and digest this season have just come out, and those are the results of the financial sector, particularly from banking stocks. However, investors need to understand that there are two types of banks to watch over this season: commercial banks and investment banks. The former covers the business cycle, while the latter covers the consumer cycle.

Investors would be surprised to learn that shares of Citigroup Inc. (NYSE: C) are down by over 5% the day after the bank reported its latest quarterly earnings results. The reason for the stock’s decline, however, has little to do with Citigroup's actual revenues and fees and more with an industry metric and regulatory speculations.

This doesn’t clear Citigroup out of trouble; otherwise, bullish traders and investors would have come running to the stock once the discount became apparent enough for everyone to close the gap and bring it back to its reasonably perceived price before the selloff took place. Investors can see the bearish momentum building up further in two simple metrics for Citigroup stock as a potential warning for the rest of the industry.

Citigroup Becomes the Latest Victim of a Worsening Consumer Sector

Credit losses and delinquency rates are on the rise. This trend has been accelerating since a couple of quarters ago, showing investors why consumer discretionary stocks like Nike Inc. (NYSE: NKE) and Lululemon Athletica Inc. (NASDAQ: LULU) both trade significantly below their 52-week high prices.

For Citigroup, this trend came in the form of a $2.7 billion credit loss, which management directly quotes as being accredited to credit losses in their card business. This is not a Citigroup-specific issue but rather an industry-wide issue, considering that peers like Bank of America Co. (NYSE: BAC) have also reported similar deteriorations in their credit card business.

Even corporate banks like Goldman Sachs Group Inc. (NYSE: GS) have decided to stay out of the consumer segment by ditching their consumer products initiative, particularly with Apple Inc. (NASDAQ: AAPL) and their credit card collaborations. Going back to Citigroup, investors can notice the rise in 90-day delinquencies for their cards.

Now at 1.5%, compared to the 1.3% from 12 years ago, 90-day delinquencies show concern for the rest of the banks and stocks involved with the health of the U.S. consumer. This is not enough to send the stock lower by 5%, however, but the following factor is.

Citigroup Stock Selloff: Regulatory Speculation and Faltering Profits Behind the Decline

Citigroup's CEO, Jane Fraser, had to defend herself against accusations and speculations from analysts during the earnings call, all centered on the thought that Citigroup might suffer from what's known as an "asset cap." Recently, another bank was deemed guilty enough of wrongdoing to have an asset cap placed on it.

Shares of Toronto-Dominion Bank (NYSE: TD) are down over 13.5% from their 52-week high after the bank was accused of money laundering. While that has nothing to do with Citigroup, analysts are rightfully concerned about the possibility of these issues spilling over to other bank names.

These fears were sparked by the falling profitability at Citigroup, specifically with one of the industry's most important metrics. The bank's return on tangible common equity (ROTCE) fell to a low of 7%, which alarmed investors, considering most peers delivered a near-double rate of return.

Bank of America, for example, reported a much higher ROTCE of 12.8% on the same day. This creates concerns about Citigroup's management's ability to effectively invest the bank's capital to deliver industry-attractive rates of return, severely compressing Citigroup's future potential earnings per share (EPS).

A 7% decline in Citigroup's EPS attracted further bearish sentiment and momentum for the stock. Starting with short sellers, the bank's short interest has been on the rise over the past quarter, from $1.5 billion to over $2.2 billion this quarter.

Broader markets agree with Citigroup stock's further potential downside, as investors can gauge through current valuation multiples compared to the rest of the finance sector. Specifically, investors can look at Citigroup's 18.5x price-to-earnings (P/E) ratio as a major discount to the finance sector's average valuation of 49.5x today.

Markets typically discount a stock when they expect lower growth or lower prices ahead, which makes sense after Citigroup's fall behind its peers in some of the important profitability metrics and price action.

Learn more about TD

Newest Stories

August 3, 2024, Paraguay. In this photo illustration, the Taiwan Semiconductor Manufacturing Company, Limited (TSMC) logo is displayed on a smartphone screen — Stock Editorial Photography
Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?

Earnings season is bringing investors the most awaited stock market results, this time not only the banking sector’s status and trends but also the semiconductor and chipmaking niche of the technology sector. Last quarter, investors gathered around the country to watch earnings results from ...

Gabriel Osorio-Mazilli | Oct 16, 2024

Champaign - Circa June 2023: Abbott Laboratories research facility. Abbott Labs is a healthcare company that makes medical and nutrition products.
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick

There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #...

Thomas Hughes | Oct 16, 2024

Salesforce building. Salesforce intends to continue its investment in integration software, customer data and SMBs.
Salesforce: Have You Seen The Latest Price Target Upgrade?

Having hit a fresh high back in March, investors in Salesforce Inc (NYSE: CRM) would have been forgiven for thinking the uptrend was set to continue. The ever-popular enterprise software platform had rallied 150% to get there. But whereas the rest of the market continued to rally into, and throu...

Sam Quirke | Oct 16, 2024

Bright Minds Biosciences Stock
Bright Minds Biosciences Stock Surges Almost 1,500%

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading under 1 million shares daily, the stock saw over 100 million shares change hands without any direct ...

Ryan Hasson | Oct 16, 2024

TickerTalk Unveils Real-Time Financial Insights and Breaking News!